Abstract 1684P
Background
Survival rates for cancer have improved steadily. Consequently, the late physical and psychological effects of treatment may negatively impact the well-being of cancer survivors. This study aimed to provide an overview of patients' lives after remission and their evolving perceptions.
Methods
In the absence of a validated questionnaire suitable to our study, we conducted a cross-sectional survey including 110 cancer survivors regardless of gender, age, and cancer site using a self-developed questionnaire designed to explore various aspects of survivors’ lives, including functional, social and emotional well-being.
Results
Median age was 58 years [37-81] and 75% of patients were women. Median follow up was 45 months [24-101]. Breast cancer was the most common cancer (44%), followed by colorectal (32.7%) and gynecologic (17.3%) cancers. All patients received chemotherapy, 33% had hormone therapy, 65.5% had radiotherapy and 96 % underwent surgery. Thirty-three patients (30%) reported ongoing fatigue and lack of energy, while 25.9% experienced cognitive decline. Persistent pain was reported by 40% of survivors. Those treated with oxaliplatin or taxane-based chemotherapy reported peripheral neuropathy in 38.4% of cases. Positive lifestyle changes were reported in 42 patients (38.9%), including adoption of healthier eating habits (40.9%), engaging in sports (31%), and an increased commitment to religious practices (14.3%). Sixty-one percent of patients resumed work, with 15.7% undergoing job reassignment. Sixty percent expressed greater appreciation for life post-cancer, and 70.9% felt their lives had acquired deeper meaning. Fear of cancer recurrence (FCR) was reported by 44 patients (40%), significantly more prevalent among females (61% vs 40%, p=0.038) and those under 50 years old (69% vs 42%, p=0.001). Sleep disturbances were reported by 41 patients (37.3%), significantly impacted by FCR (OR= 3.77 [1.12-7.87]) and pain (OR= 2.56 [1.08-5.87]).
Conclusions
Years after cancer, patients have to deal with changes concerning their physical and emotional well-being. Thus, treatment protocols should be well-considered and follow-up programs should target these disturbances timely.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1687P - Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients
Presenter: María Jesús Rubio Pérez
Session: Poster session 11
1688P - Psychosocial distress and spirituality among elderly patients with cancer in Nigeria
Presenter: Zainab Ogunjimi
Session: Poster session 11
1689TiP - The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
Presenter: Domenico Galetta
Session: Poster session 11
1692P - A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
Presenter: Xinan Sheng
Session: Poster session 11
1693P - CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
Presenter: Laurence Albiges
Session: Poster session 11
1695P - Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
Presenter: Ulka Vaishampayan
Session: Poster session 11
1696P - A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results
Presenter: Saby George
Session: Poster session 11
1697P - Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
Presenter: Sarmad Sadeghi
Session: Poster session 11
1698P - Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Presenter: Balaji Venugopal
Session: Poster session 11